Drug Trial Radar · NCT04167358
Linerixibat Long-term Safety, and Tolerability Study
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
242
Actual
Start
Jul 8, 2020
Primary completion
Sep 30, 2026
Study completion Sep 30, 2026
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Nov 18, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, non-comparator, global, multi-center, long-term safety study for evaluating safety and tolerability of linerixibat in participants with cholestatic pruritus in primary biliary cholangitis (PBC) who participated in a prior clinical trial with linerixibat (BAT117123 \[NCT01899703\], 201000 GLIMMER \[NCT02966834\] (group 1) or 212620 GLISTEN \[NCT00210418\]) (group 2). All participants will receive open-label linerixibat for the duration of the study. The study duration is expected to last until the study's end or until linerixibat can be lawfully made available to participants. However, the total duration of study participation will vary by participant depending upon the time of entry relative to study end in their respective country.
Conditions
- Cholestasis
Interventions
LinerixibatDrug
All participants will receive linerixibat.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with non-serious adverse events (AEs) and Serious AEs (SAEs)Time frame: Up to 66 months
- Number of participants with Severe AEsTime frame: Up to 66 months
Locations
94 sites in 17 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Sacramento, California
GSK Investigational Site
West Hollywood, California
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Detroit, Michigan
GSK Investigational Site
New York, New York
GSK Investigational Site
Durham, North Carolina
GSK Investigational Site
Morrisville, North Carolina
GSK Investigational Site
Philadelphia, Pennsylvania
GSK Investigational Site
Dallas, Texas
GSK Investigational Site
Houston, Texas
GSK Investigational Site
Seattle, Washington
GSK Investigational Site
Buenos Aires, Argentina
GSK Investigational Site
Capital Federal, Argentina
GSK Investigational Site
Ciudad Autonoma de Bueno, Argentina
GSK Investigational Site
Ciudad AutOnoma de Buenos Aire, Argentina
GSK Investigational Site
Rosario, Argentina
GSK Investigational Site
Santa Fe, Argentina
GSK Investigational Site
Botucatu, Brazil
GSK Investigational Site
Brasília, Brazil
GSK Investigational Site
Salvador, Brazil
GSK Investigational Site
Porto Alegre, Rio Grande do Sul, Brazil
GSK Investigational Site
Sofia, Bulgaria
GSK Investigational Site
Edmonton, Alberta, Canada
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Beijing, China
GSK Investigational Site
Beijing, China
GSK Investigational Site
Changchun, China
GSK Investigational Site
Chongqing, China
GSK Investigational Site
Guangzhou, China
GSK Investigational Site
Nanchang, China
GSK Investigational Site
Nanjing, China
GSK Investigational Site
Shanghai, China
GSK Investigational Site
Tianjin, China
GSK Investigational Site
Pilsen, Czechia
GSK Investigational Site
Prague, Czechia
GSK Investigational Site
Lille, France
GSK Investigational Site
Erlangen, Germany
GSK Investigational Site
Münster, Germany
GSK Investigational Site
Haifa, Israel
GSK Investigational Site
Holon, Israel
Showing 40 of 94 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.